11.12.2018 • NewsDede WillamsGilead SciencesRoche

Gilead Nabs Roche Pharma Chief

Gilead Nabs Roche Pharma Chief
Gilead Nabs Roche Pharma Chief

Gilead Sciences has nabbed Daniel O’Day, head of Roche’s pharma business, as its new chief executive to replace current CEO John Milligan, with effective from March 2019. Both Milligan and Chairman John Martin have announced plans to leave the US drugmaker at the end of 2018.

O’Day joined Roche in 1987 and held various roles with the company in the US before moving in 1998 to headquarters in Basel, Switzerland. Roche has named William Anderson, current CEO of its Genentech arm, to replace O’Day next year, while Gregg Alton will serve as interim CEO at Gilead from Jan. 1, 2019 until O’Day’s start date of Mar. 1.

The three decades of oncology and global commercial expertise O’Day gained at Roche are expected to help Gilead build its own global presence in its new fields of oncology and inflammation as well as transact more acquisitions and in-licensing deals, analysts said.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read